Galapagos (NASDAQ:GLPG) Downgraded by Kepler Capital Markets to Reduce

Kepler Capital Markets lowered shares of Galapagos (NASDAQ:GLPG) from a hold rating to a reduce rating in a report issued on Wednesday, Marketbeat Ratings reports.

Several other research analysts have also recently weighed in on the company. Leerink Partners assumed coverage on Galapagos in a research report on Monday, September 9th. They set a “market perform” rating and a $24.00 price target for the company. Royal Bank of Canada lowered their price target on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a report on Friday, November 1st. Raymond James downgraded shares of Galapagos from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. Finally, Leerink Partnrs raised shares of Galapagos to a “hold” rating in a research note on Monday, September 9th. Two analysts have rated the stock with a sell rating and six have issued a hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.75.

Galapagos Trading Down 3.9 %

NASDAQ:GLPG opened at $25.64 on Wednesday. The company’s fifty day moving average price is $28.76 and its 200-day moving average price is $27.54. Galapagos has a 1-year low of $24.16 and a 1-year high of $42.46.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC lifted its holdings in Galapagos by 56.7% in the 2nd quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 446 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Galapagos by 140.7% in the third quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 736 shares during the period. Signaturefd LLC increased its position in Galapagos by 48.1% during the second quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 1,258 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Galapagos by 63.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 1,510 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 814 shares during the last quarter. 32.46% of the stock is owned by hedge funds and other institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.